Cargando…

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

BACKGROUND: The tumour–stroma ratio (TSR) has proven to be an independent prognostic factor in colon cancer. METHODS: Haematoxylin eosin tissue slides of patients from the AVANT trial were microscopically scored for TSR and categorised as stroma -low or stroma -high. Scores were correlated to the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zunder, Stéphanie M., van Pelt, Gabi W., Gelderblom, Hans J., Mancao, Christoph, Putter, Hein, Tollenaar, Rob A., Mesker, Wilma E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048031/ https://www.ncbi.nlm.nih.gov/pubmed/29755119 http://dx.doi.org/10.1038/s41416-018-0083-0

Ejemplares similares

Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study
por: Smit, Marloes A., et al.
Publicado: (2021)

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
por: Smit, Marloes, et al.
Publicado: (2019)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Tumor stroma as contributing factor in the lymph node metastases process?
por: Mesker, Wilma E., et al.
Publicado: (2019)

The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer
por: Vangangelt, Kiki M.H., et al.
Publicado: (2020)

Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2018)

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2019)

Deep learning based tumor–stroma ratio scoring in colon cancer correlates with microscopic assessment
por: Smit, Marloes A., et al.
Publicado: (2023)

Standardization of the tumor-stroma ratio scoring method for breast cancer research
por: Hagenaars, Sophie C., et al.
Publicado: (2022)

e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study
por: Smit, Marloes A, et al.
Publicado: (2021)

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients
por: Mesker, Wilma E., et al.
Publicado: (2009)

The role of artificial intelligence to quantify the tumour-stroma ratio for survival in colorectal cancer
por: Smit, Marloes A, et al.
Publicado: (2020)

The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
por: Kramer, C. J. H., et al.
Publicado: (2018)

N-Glycomic Signature of Stage II Colorectal Cancer and Its Association With the Tumor Microenvironment
por: Boyaval, Fanny, et al.
Publicado: (2021)

Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer
por: Mesker, W E, et al.
Publicado: (2015)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT
por: Polack, Meaghan, et al.
Publicado: (2022)

Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
por: van Pelt, G. W., et al.
Publicado: (2018)

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer
por: Sandberg, Tessa P., et al.
Publicado: (2019)

The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage
por: Mesker, Wilma E., et al.
Publicado: (2007)

Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2019)

Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study
por: Vogelaar, F. J., et al.
Publicado: (2016)

The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer
por: van Pelt, G.W., et al.
Publicado: (2019)

Tumour‐stroma ratio has poor prognostic value in nonpedunculated T1 colorectal cancer: A multicentre case‐cohort study
por: Dang, Hao, et al.
Publicado: (2021)

A stroma‐related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early‐stage colon cancer
por: Zhou, Rui, et al.
Publicado: (2020)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study
por: Eriksen, Ann Christina, et al.
Publicado: (2018)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
por: Kairaluoma, Valtteri, et al.
Publicado: (2020)

An immune, stroma, and epithelial–mesenchymal transition‐related signature for predicting recurrence and chemotherapy benefit in stage II–III colorectal cancer
por: Cai, Du, et al.
Publicado: (2023)

Tumour-stroma ratio and prognosis in gastric adenocarcinoma
por: Kemi, Niko, et al.
Publicado: (2018)

N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression
por: Holst, Stephanie, et al.
Publicado: (2016)

Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
por: Bayoumi, Yasser, et al.
Publicado: (2014)

Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study
por: Vogelaar, F Jeroen, et al.
Publicado: (2010)

Hypoxic Signalling in Tumour Stroma
por: Laitala, Anu, et al.
Publicado: (2018)

The prognostic significance of tumour-stroma ratio in endometrial carcinoma
por: Panayiotou, Hannah, et al.
Publicado: (2015)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9507ko6mij5kg2n7b3rqvjc431